Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Meetings
Highlights
Highlights
Summaries and high points from meetings about lung cancer and other thoracic neoplasms.
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
lungcanc
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy
Single-Agent Pembrolizumab Active Against STK11– and KEAP1– Mutated NSCLC According to KEYNOTE-042 Analysis
Best of the 16th World Conference on Lung Cancer in Peru
lungcanc
Best of the 16th WCLC in Athens, Greece
lungcanc
4th AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the...
lungcanc
1
2
3
4
Page 4 of 4
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
